PT - JOURNAL ARTICLE AU - Gyasi, Samuel Fosu AU - Donkoh, Emmanuel Timmy AU - Frempong, Samuel AU - Asamoah, Akwasi AU - Raji, Abdul Sakibu AU - Baidoo, Rabbi Coffie AU - Isaac, Williams AU - Essel, Dorcas AU - Asakiya, Herbert Alemiya TI - Evaluation of anti-SARS-CoV-2 antibody response to COVID-19 vaccine deployment in the Bono Region, Ghana AID - 10.1101/2022.06.09.22276192 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.09.22276192 4099 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276192.short 4100 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276192.full AB - Background Preliminary data across the globe shows that the AstraZeneca vaccine was highly effective in preventing not only the symptoms but also the transmission of the SARS-CoV-2 virus. In Ghana, data on the immune response generated by different vaccination doses is lacking. The present study aimed to compare the anti-SARS-CoV-2 antibody response among single and double-vaccinated versus unvaccinated individuals.Methods A case-control design was employed for this study. Seventy-nine participants (35 vaccinated, 44 unvaccinated) were recruited from the Sunyani West Municipality and screened for the presence of SARS-CoV-2 specific IgG and IgM antibodies in plasma samples using a Standard COVID IgG and IgM Combo FIA test. Data analysis was carried out with STATA (Version 21).Results The current study showed that mean IgG levels among vaccine groups (Group-1: Not vaccinated, Group-2: 1 dose, Group-3: 2 doses) differed significantly (F2, 76=11.457, p<.001) between Group-1 and Group-3; and between Group-2 and Group-3. Participants in Group-2 and Group-3 were 4.1 and 12.5 times more likely to develop more antibody responses compared to their counterparts in Group-1 respectively.Conclusion The study showed that participants who took one shot of the vaccine, as well as those who took two shots of the AstraZeneca Vaccine, were 4.1 and 12.5 times more likely to develop a greater antibody response than those who did not receive the vaccine respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research activities and protocols were approved by the Committee for Human Research and Ethics at the University of Energy and Natural Resources with reference number CHRE/AP/09/021. The purpose of the study and all procedures were explained to participants before consent was taken. All participants were provided with informed consent forms and were included after the endorsement of the form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not Applicable